<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	>

<channel>
	<title>HEALTH REFORM WATCH</title>
	<atom:link href="http://www.healthreformwatch.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.healthreformwatch.com</link>
	<description>A Web Log of Seton Hall Law School's Center for Health &#38; Pharmaceutical Law &#38; Policy</description>
	<pubDate>Wed, 16 May 2012 02:40:06 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.7</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Of Drug and Device and a Lack of Personal Jurisdiction</title>
		<link>http://www.healthreformwatch.com/2012/05/15/of-drug-and-device-and-a-lack-of-personal-jurisdiction/</link>
		<comments>http://www.healthreformwatch.com/2012/05/15/of-drug-and-device-and-a-lack-of-personal-jurisdiction/#comments</comments>
		<pubDate>Wed, 16 May 2012 02:34:38 +0000</pubDate>
		<dc:creator>Michael Ricciardelli</dc:creator>
		
		<category><![CDATA[Drugs & Medical Devices]]></category>

		<category><![CDATA[Health Law]]></category>

		<category><![CDATA[Darvocet]]></category>

		<category><![CDATA[Drug & Device]]></category>

		<category><![CDATA[Drug and Device]]></category>

		<category><![CDATA[Health Reform]]></category>

		<category><![CDATA[Medical Malpractice]]></category>

		<category><![CDATA[Pharma]]></category>

		<category><![CDATA[pharmaceutical industry]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12923</guid>
		<description><![CDATA[As much as I write about medical malpractice, it seems only fair that I devote a post and direct our fair readers to the other side of the bar: The Drug and Device blog put out by a number of Dechert, LLP attorneys involved in pharmaceutical and medical device product liability litigation&#8211; from the defense [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/05/15/of-drug-and-device-and-a-lack-of-personal-jurisdiction/feed/</wfw:commentRss>
		</item>
		<item>
		<title>First Circuit Finds Generic Drugmaker Had State Law Duty to Stop Selling Unsafe Drug</title>
		<link>http://www.healthreformwatch.com/2012/05/13/first-circuit-finds-generic-drugmaker-had-state-law-duty-to-stop-selling-unsafe-drug/</link>
		<comments>http://www.healthreformwatch.com/2012/05/13/first-circuit-finds-generic-drugmaker-had-state-law-duty-to-stop-selling-unsafe-drug/#comments</comments>
		<pubDate>Sun, 13 May 2012 19:36:03 +0000</pubDate>
		<dc:creator>Kate Greenwood</dc:creator>
		
		<category><![CDATA[Health Law]]></category>

		<category><![CDATA[Prescription Drugs]]></category>

		<category><![CDATA[Drug & Device]]></category>

		<category><![CDATA[Drug and Device]]></category>

		<category><![CDATA[FDA]]></category>

		<category><![CDATA[generic drugs]]></category>

		<category><![CDATA[Health Care Reform]]></category>

		<category><![CDATA[Health Reform]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12909</guid>
		<description><![CDATA[
Earlier this month, the First Circuit surprised observers when it held, in Bartlett v. Mutual Pharmaceutical, that a state law product liability suit founded on the claim that a generic drug was unreasonably dangerous due to a design defect was not preempted by the Federal Food, Drug, and Cosmetic Act (FDCA).  In coming to its [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/05/13/first-circuit-finds-generic-drugmaker-had-state-law-duty-to-stop-selling-unsafe-drug/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Benefit Concert for Africa Surgery in Morristown, NJ</title>
		<link>http://www.healthreformwatch.com/2012/05/10/benefit-concert-for-africa-surgery-in-morristown-nj/</link>
		<comments>http://www.healthreformwatch.com/2012/05/10/benefit-concert-for-africa-surgery-in-morristown-nj/#comments</comments>
		<pubDate>Fri, 11 May 2012 02:53:12 +0000</pubDate>
		<dc:creator>Michael Ricciardelli</dc:creator>
		
		<category><![CDATA[Global Health Care]]></category>

		<category><![CDATA[Treatment]]></category>

		<category><![CDATA[Africa Surgery]]></category>

		<category><![CDATA[Global Health]]></category>

		<category><![CDATA[Health Care Reform]]></category>

		<category><![CDATA[Health Reform]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12900</guid>
		<description><![CDATA[Dicey Riley Band
To present a BENEFIT concert for Surgical Efforts in Sierra Leone, West Africa
Featuring Traditional Irish and Celtic Music and Song, Plus the
Bethel AME and Assumption Children&#8217;s Choirs
Singing selected choral works
Refreshments donated by parishioners
Saturday, May 12, 2012, 7:30-9:30 pm
Assumption Church
91 Maple Ave., Morristown, NJ 07960
Suggested donation: $15 per adult, Children Free
All proceeds go directly [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/05/10/benefit-concert-for-africa-surgery-in-morristown-nj/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Lower Cost, But at What Cost?</title>
		<link>http://www.healthreformwatch.com/2012/05/08/lower-cost-but-at-what-cost/</link>
		<comments>http://www.healthreformwatch.com/2012/05/08/lower-cost-but-at-what-cost/#comments</comments>
		<pubDate>Wed, 09 May 2012 04:25:22 +0000</pubDate>
		<dc:creator>Zack Buck</dc:creator>
		
		<category><![CDATA[Mental Illness]]></category>

		<category><![CDATA[Treatment]]></category>

		<category><![CDATA[Cost Control]]></category>

		<category><![CDATA[Health Care Reform]]></category>

		<category><![CDATA[Health Reform]]></category>

		<category><![CDATA[Mental Health]]></category>

		<category><![CDATA[psychiatric hospital]]></category>

		<category><![CDATA[Quality Improvement]]></category>

		<category><![CDATA[residential health care facilities]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12892</guid>
		<description><![CDATA[Late last month, Essex County Mental Health Association director Bob Davison went undercover to experience the current conditions at Dover Woods, a residential psychiatric facility in Toms River, New Jersey.  His subsequent report was published in the Newark Star-Ledger.  It paints a bleak and jarring account of life within the large mental health care facility, [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/05/08/lower-cost-but-at-what-cost/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Models of Patient Safety</title>
		<link>http://www.healthreformwatch.com/2012/05/03/models-of-patient-safety/</link>
		<comments>http://www.healthreformwatch.com/2012/05/03/models-of-patient-safety/#comments</comments>
		<pubDate>Fri, 04 May 2012 01:59:26 +0000</pubDate>
		<dc:creator>Frank Pasquale</dc:creator>
		
		<category><![CDATA[Electronic Medical Records]]></category>

		<category><![CDATA[IT]]></category>

		<category><![CDATA[Medical Journals]]></category>

		<category><![CDATA[Medical Malpractice]]></category>

		<category><![CDATA[Health Care Reform]]></category>

		<category><![CDATA[Health Law]]></category>

		<category><![CDATA[Health Reform]]></category>

		<category><![CDATA[HIT]]></category>

		<category><![CDATA[Quality Improvement]]></category>

		<category><![CDATA[surgical checklist]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12772</guid>
		<description><![CDATA[If one jumbo jet crashed in the US each day for a week, we&#8217;d expect the FAA to shut down the industry until the problem was figured out. But in our health care system, roughly 250 people die each day due to preventable error. A vice president at a health care quality company says that &#8220;If [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/05/03/models-of-patient-safety/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Tara Ragone on Medical Loss Ratio Rebates in New Jersey</title>
		<link>http://www.healthreformwatch.com/2012/05/01/tara-ragone-on-medical-loss-ratio-rebates-in-new-jersey/</link>
		<comments>http://www.healthreformwatch.com/2012/05/01/tara-ragone-on-medical-loss-ratio-rebates-in-new-jersey/#comments</comments>
		<pubDate>Wed, 02 May 2012 05:04:24 +0000</pubDate>
		<dc:creator>Michael Ricciardelli</dc:creator>
		
		<category><![CDATA[Health Law]]></category>

		<category><![CDATA[Private Insurance]]></category>

		<category><![CDATA[ACA]]></category>

		<category><![CDATA[Health Care Reform]]></category>

		<category><![CDATA[Health Reform]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12764</guid>
		<description><![CDATA[Seton Hall Law Research Fellow &#38; Lecturer in Law, Tara Ragone, appeared in the award winning business publication NJBIZ regarding rebates to consumers from health insurers who have failed to meet their Medical Loss Ratio requirements under the ACA.
NJBIZ notes:
New Jersey consumers  will receive an estimated $106 million in health insurance rebates from  [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/05/01/tara-ragone-on-medical-loss-ratio-rebates-in-new-jersey/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Recommended Reading: The FDA on Its Post-2007 Safety Ramp-Up and Barbara Evans on the Ethics of FDA-Mandated Postmarketing Studies</title>
		<link>http://www.healthreformwatch.com/2012/04/29/recommended-reading-the-fda-on-its-post-2007-safety-ramp-up-and-barbara-evans-on-the-ethics-of-fda-mandated-postmarketing-studies/</link>
		<comments>http://www.healthreformwatch.com/2012/04/29/recommended-reading-the-fda-on-its-post-2007-safety-ramp-up-and-barbara-evans-on-the-ethics-of-fda-mandated-postmarketing-studies/#comments</comments>
		<pubDate>Sun, 29 Apr 2012 20:34:34 +0000</pubDate>
		<dc:creator>Kate Greenwood</dc:creator>
		
		<category><![CDATA[FDA]]></category>

		<category><![CDATA[Recommended Reading]]></category>

		<category><![CDATA[Drug and Device]]></category>

		<category><![CDATA[Ethics]]></category>

		<category><![CDATA[Health Care Reform]]></category>

		<category><![CDATA[Health Reform]]></category>

		<category><![CDATA[Postmarket Review]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12757</guid>
		<description><![CDATA[
The FDA has released a report &#8212; Advances in FDA&#8217;s Safety Program for Marketed Drugs &#8212; in which the agency declares that, as a result of reforms implemented following the passage of the Food and Drug Administration Amendments Act (FDAAA) in 2007, it &#8220;now oversees the safety of both innovator and generic marketed drugs with [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/04/29/recommended-reading-the-fda-on-its-post-2007-safety-ramp-up-and-barbara-evans-on-the-ethics-of-fda-mandated-postmarketing-studies/feed/</wfw:commentRss>
		</item>
		<item>
		<title>CIAs: OIG&#8217;s Favorite Enforcement Tool</title>
		<link>http://www.healthreformwatch.com/2012/04/25/cias-oigs-favorite-enforcement-tool/</link>
		<comments>http://www.healthreformwatch.com/2012/04/25/cias-oigs-favorite-enforcement-tool/#comments</comments>
		<pubDate>Thu, 26 Apr 2012 03:05:22 +0000</pubDate>
		<dc:creator>John Barry</dc:creator>
		
		<category><![CDATA[Compliance]]></category>

		<category><![CDATA[Health Law]]></category>

		<category><![CDATA[CIA]]></category>

		<category><![CDATA[Corporate Compliance]]></category>

		<category><![CDATA[Corporate Integrity Agreement]]></category>

		<category><![CDATA[Fraud & Abuse]]></category>

		<category><![CDATA[Fraud and Abuse]]></category>

		<category><![CDATA[Health Care Reform]]></category>

		<category><![CDATA[Health Reform]]></category>

		<category><![CDATA[OIG]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12745</guid>
		<description><![CDATA[In an attempt to stem health care fraud, the government&#8217;s use of Corporate Integrity Agreements (CIAs) is growing. In Professor Zack Buck&#8217;s Health Care Fraud and Abuse class here at Seton Hall Law, students were given the benefit of  a discussion on the topic by two industry veterans, Tim Grimes and Brett Bissey.  Grimes is [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/04/25/cias-oigs-favorite-enforcement-tool/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Online Graduate Certificate Programs in Pharmaceutical &#038; Medical Device Law and Health &#038; Hospital Law</title>
		<link>http://www.healthreformwatch.com/2012/04/23/online-graduate-certificate-programs-2/</link>
		<comments>http://www.healthreformwatch.com/2012/04/23/online-graduate-certificate-programs-2/#comments</comments>
		<pubDate>Tue, 24 Apr 2012 00:30:50 +0000</pubDate>
		<dc:creator>Michael Ricciardelli</dc:creator>
		
		<category><![CDATA[Health Law]]></category>

		<category><![CDATA[Seton Hall Law]]></category>

		<category><![CDATA[Center for Health and Pharmaceutical Law & Policy]]></category>

		<category><![CDATA[Compliance]]></category>

		<category><![CDATA[Drug & Device]]></category>

		<category><![CDATA[Drug and Device]]></category>

		<category><![CDATA[Health Reform]]></category>

		<category><![CDATA[Online Health & Hospital Law]]></category>

		<category><![CDATA[Pharmaceutical & Medical Device Law]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12737</guid>
		<description><![CDATA[The  next sessions for the Seton Hall Law Online Graduate Certificate   Programs will commence in June, 2012. These 8-week non-degree   programs are designed for individuals who seek a greater understanding   of key aspects of the health care field.
The Pharmaceutical &#38; Medical Device Law &#38; Compliance Program will begin [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/04/23/online-graduate-certificate-programs-2/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Risperdal: Low Hanging Fruit for States with Medicaid Deficits?</title>
		<link>http://www.healthreformwatch.com/2012/04/20/risperdal-low-hanging-fruit-for-states-with-medicaid-deficits/</link>
		<comments>http://www.healthreformwatch.com/2012/04/20/risperdal-low-hanging-fruit-for-states-with-medicaid-deficits/#comments</comments>
		<pubDate>Fri, 20 Apr 2012 16:02:50 +0000</pubDate>
		<dc:creator>Michael Ricciardelli</dc:creator>
		
		<category><![CDATA[Health Law]]></category>

		<category><![CDATA[Pharma]]></category>

		<category><![CDATA[Prescription Drugs]]></category>

		<category><![CDATA[Compliance]]></category>

		<category><![CDATA[False Claims Act]]></category>

		<category><![CDATA[FCA]]></category>

		<category><![CDATA[Fraud and Abuse]]></category>

		<category><![CDATA[Health Care Reform]]></category>

		<category><![CDATA[Health Reform]]></category>

		<category><![CDATA[pharmaceutical industry]]></category>

		<category><![CDATA[Risperdal]]></category>

		<guid isPermaLink="false">http://www.healthreformwatch.com/?p=12732</guid>
		<description><![CDATA[Think of it as a clarion call, a shot across the bow, or even the smell of carrion wafting towards the nostrils of bean counters and state administrators everywhere&#8211;but any way you look at it, be sure that the Risperdal verdict of $1.2 billion dollars against Johnson &#38; Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., [...]]]></description>
		<wfw:commentRss>http://www.healthreformwatch.com/2012/04/20/risperdal-low-hanging-fruit-for-states-with-medicaid-deficits/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>

